How Israeli HMOs Secure Biometric and Genetic Data Under Amendment 13

Israeli health maintenance organisations face unique obligations when securing biometric and genetic data. Amendment 13 to the Privacy Protection Regulations establishes rigorous requirements for organisations that collect, process, and transmit highly sensitive health information, including genetic markers, biometric identifiers, and personally identifiable medical records. For HMOs managing millions of patient interactions, Amendment 13 creates compliance, architectural, and operational challenges that extend far beyond traditional data compliance frameworks.

These organisations operate in an environment where biometric authentication systems, genetic testing platforms, and electronic health records intersect with third-party laboratories, research institutions, and government reporting systems. Each data exchange introduces risk. Each storage system requires specific controls. Amendment 13 mandates that organisations implement technical and procedural safeguards proportionate to the sensitivity of the data, enforce strict access controls, and maintain comprehensive audit trails that demonstrate continuous compliance.

This post explains how Israeli HMOs interpret and operationalise Amendment 13 requirements, what technical architectures support compliant biometric and genetic data workflows, and how organisations translate regulatory language into defensible security posture.

Executive Summary

Amendment 13 to Israel’s Privacy Protection Regulations imposes heightened obligations on organisations handling biometric and genetic data. For health maintenance organisations, compliance requires layered technical controls, role-based access control (RBAC), encryption at rest and in transit, and audit mechanisms that track every data interaction across internal systems and external partners. Israeli HMOs address these requirements by implementing zero trust architecture, deploying data security posture management (DSPM) tools, and integrating content-aware enforcement layers that inspect, classify, and control sensitive data in motion. The challenge is not simply meeting regulatory mandates but operationalising them across complex, distributed workflows involving laboratories, researchers, insurers, and government agencies. Organisations that succeed combine policy-driven data governance with technical enforcement, ensuring that biometric and genetic data remains protected, traceable, and audit-ready throughout its lifecycle.

Key Takeaways

1. Heightened Data Protection Standards. Amendment 13 to Israel’s Privacy Protection Regulations imposes strict requirements on Israeli HMOs for securing biometric and genetic data, mandating encryption, access controls, and data minimization to protect sensitive information.
2. Robust Technical Safeguards. HMOs must implement advanced security measures like AES-256 encryption, zero trust architecture, and multi-factor authentication to ensure data protection at rest and in transit across complex workflows.
3. Comprehensive Audit and Compliance. Maintaining immutable audit trails and integrating with SIEM and SOAR platforms are critical for HMOs to demonstrate continuous compliance with Amendment 13 and respond effectively to incidents.
4. Third-Party Risk Management. Israeli HMOs are accountable for ensuring third-party processors adhere to equivalent security standards, requiring rigorous vendor assessments, secure data exchange mechanisms, and detailed contracts to mitigate risks.

Amendment 13 Establishes Heightened Requirements for Biometric and Genetic Data

Amendment 13 to the Privacy Protection Regulations defines biometric data as physiological or behavioural characteristics used to identify individuals, including fingerprints, retinal scans, voiceprints, and facial geometry. Genetic data encompasses information derived from DNA, RNA, or chromosomal analysis that reveals hereditary traits, disease predisposition, or familial relationships. Both categories receive special regulatory status because of their uniqueness, immutability, and potential for misuse.

The amendment mandates that organisations collecting or processing biometric or genetic data implement security measures commensurate with the data’s sensitivity. This includes encryption, access controls, data minimization, and transparency obligations. Organisations must document the legal basis for processing, notify individuals of data use, and obtain explicit consent where required. For Israeli HMOs, these requirements intersect with existing obligations under the Patient Rights Act, the National Health Insurance Law, and sector-specific directives from the Ministry of Health.

Consent mechanisms must be specific, informed, and revocable. Organisations must explain what data will be collected, how it will be used, who will access it, and how long it will be retained. When biometric data is used for authentication, organisations must offer alternative authentication methods. When genetic data is collected for research, organisations must separate clinical care from research activities and obtain distinct consent for each.

Amendment 13 mandates that organisations collect only the biometric and genetic data necessary for a specified, legitimate purpose. Data minimisation reduces risk by limiting the volume of sensitive data in scope. Purpose limitation ensures that data collected for one purpose is not repurposed without additional legal basis. Israeli HMOs implement attribute-based access control (ABAC) systems that evaluate data classification, user role, and intended purpose before granting access. These systems integrate with data loss prevention (DLP) tools that inspect data in transit, block unauthorised exfiltration, and log every access event.

Encryption and Access Control Requirements Across Storage and Transit

Amendment 13 requires organisations to encrypt biometric and genetic data at rest and in transit. Israeli HMOs implement AES-256 encryption standards aligned with National Cyber Directorate guidance and international frameworks such as NIST 800-171 and FIPS. Encryption at rest applies to databases, file servers, backup systems, and removable media. Organisations deploy full-disk encryption, volume-level encryption, or application-layer encryption depending on system architecture. Encryption keys are managed through dedicated key management systems that enforce separation of duties, key rotation policies, and audit logging.

Encryption in transit applies to data moving between systems, across networks, and to external partners. HMOs implement TLS 1.3 for data transmitted over public networks and IPsec or VPN tunnels for site-to-site connections. For highly sensitive genetic data shared with research institutions or government agencies, organisations deploy end-to-end encryption that protects data throughout its journey.

Access control is the primary mechanism through which Israeli HMOs enforce Amendment 13 requirements. Role-based access control assigns permissions based on job function, ensuring that clinicians, laboratory technicians, researchers, and administrative staff can access only the data necessary for their responsibilities. Attribute-based access control extends this model by evaluating additional context such as data classification, user location, device posture, and time of access.

Role definitions must be granular and regularly reviewed. Permissions are documented in access control matrices that map roles to data assets and approved actions. These matrices are reviewed quarterly and updated when roles change or new data categories are introduced. Every access decision is logged, and anomalous access patterns trigger alerts for investigation.

Israeli HMOs implement multi-factor authentication (MFA) as a baseline control for systems processing biometric and genetic data. Privileged access management is critical for protecting administrative accounts with elevated permissions. HMOs implement just-in-time access provisioning, time-limited privilege escalation, and session recording for privileged users. Privileged access management platforms integrate with identity providers, ticketing systems, and approval workflows. When an administrator requests elevated access, the system validates the request, grants temporary credentials, and logs the session.

Audit Trails and Logging Requirements for Regulatory Defensibility

Amendment 13 requires organisations to maintain comprehensive audit logs that document who accessed biometric and genetic data, when, why, and what actions were performed. Israeli HMOs implement centralised logging platforms that collect events from identity and access management (IAM) systems, data repositories, network devices, and applications. Log data includes user identity, data asset accessed, action performed, timestamp, source IP address, and outcome. Logs are immutable, tamper-proof, and retained for periods aligned with regulatory requirements.

Audit trails must be accessible to regulators on demand. Organisations implement search and reporting tools that enable rapid retrieval of access events for specific users, data assets, or time periods. Immutability is essential for audit trails to serve as reliable evidence. Israeli HMOs implement write-once-read-many storage for log data. Logs are digitally signed or cryptographically hashed to provide tamper evidence, enabling organisations to prove that audit records have not been modified.

Immutable logging platforms integrate with compliance mapping tools that link log events to specific Amendment 13 requirements. This enables organisations to demonstrate during audits that every regulatory obligation is supported by corresponding technical controls and verifiable evidence. Tamper-evident audit records also support forensic investigations, enabling organisations to reconstruct incident sequences, identify root causes, and determine whether policy violations contributed to breaches.

Audit trails are most effective when integrated with SIEM platforms that correlate log data across systems and generate actionable alerts. Israeli HMOs deploy SIEM platforms that ingest logs from multiple sources, then apply correlation rules to detect patterns indicative of policy violations or unauthorised access. SOAR platforms extend SIEM capabilities by automating incident response workflows. When an alert is triggered, SOAR platforms can automatically revoke user access, isolate affected systems, and notify incident response teams.

Compliance reporting platforms consume audit data and generate reports mapped to Amendment 13 requirements. These reports include evidence of encryption enforcement, access control policies, consent management, and data retention. Organisations use these reports during regulatory audits, internal compliance reviews, and third-party assessments.

Third-Party Data Sharing and Processor Accountability

Israeli HMOs frequently share biometric and genetic data with external laboratories, research institutions, insurers, and government agencies. Amendment 13 requires organisations to ensure that third-party processors implement equivalent security controls. Organisations remain accountable for data protection even when processing is outsourced.

Third-party risk management (TPRM) begins with vendor assessment. HMOs evaluate prospective processors against security criteria aligned with Amendment 13, including encryption capabilities, access control mechanisms, and incident response procedures. Organisations require vendors to complete detailed questionnaires, provide evidence of compliance certifications, and submit to assessments.

Contracts with third-party processors must specify data protection obligations, including encryption requirements, access restrictions, audit rights, and notification timelines for security incidents. Contracts include provisions for termination, data return, and destruction upon contract expiry. Organisations conduct periodic audits of third-party processors, reviewing access logs, security configurations, and compliance evidence.

Sharing genetic data with external parties introduces risk at the point of transmission and at rest within the recipient’s environment. Israeli HMOs implement secure data exchange mechanisms that encrypt data end to end, authenticate recipients, and provide proof of delivery. Secure file transfer platforms support encryption, access controls, and audit logging. When genetic data is shared with a research institution, the sender uploads the data to a secure platform, specifies authorised recipients, and defines expiry dates or access limits. The recipient authenticates using multi-factor authentication and downloads the data over an encrypted channel. The platform logs every access event, providing an immutable record of data sharing activities.

Data processing agreements define the responsibilities of HMOs and third-party processors. These agreements specify the purpose of processing, the types of data shared, the security controls required, and the procedures for incident response and breach notification. Israeli HMOs implement third-party risk management platforms that track processor compliance status, flag contract renewals, and generate alerts when processors fail to meet security standards.

Anonymisation and Pseudonymisation Techniques for Research Workflows

Research activities often require access to genetic data but not personally identifiable information. Amendment 13 encourages organisations to anonymise or pseudonymise data when possible. Anonymisation irreversibly removes identifiers, rendering data non-personal. Pseudonymisation replaces identifiers with pseudonyms, allowing re-identification under controlled conditions.

Israeli HMOs apply anonymisation techniques when sharing genetic data with external research institutions. Anonymisation methods include data aggregation, generalisation, suppression, and noise addition. Organisations evaluate re-identification risk by assessing whether anonymised data can be linked to individuals through auxiliary information. When re-identification risk exceeds acceptable thresholds, organisations apply additional techniques or decline to share data.

Pseudonymisation is preferred when data must remain linkable for longitudinal research or clinical follow-up. Pseudonymisation replaces patient identifiers with pseudonyms generated through cryptographic hashing or tokenisation. The mapping between pseudonyms and identifiers is stored separately, access-controlled, and encrypted. Only authorised personnel with a legitimate need can access the mapping.

Data masking and tokenisation are practical techniques for protecting genetic markers in non-production environments. Data masking replaces sensitive values with fictitious but realistic data, enabling development, testing, and analytics workflows without exposing real genetic information. Israeli HMOs implement data masking for development and testing environments. Tokenisation is used when genetic data must be shared with third parties for specific purposes such as billing or logistics coordination. Tokens preserve the format of genetic identifiers, enabling systems to process data without exposing actual genetic markers.

Incident Response and Breach Notification Under Amendment 13

Amendment 13 requires organisations to notify the Privacy Protection Authority and affected individuals when a data breach involving biometric or genetic data occurs. Israeli HMOs implement incident response plans that define roles, responsibilities, escalation procedures, and communication protocols. Plans include detection mechanisms, containment procedures, forensic investigation steps, and notification templates. Breach detection relies on SIEM platforms, anomaly detection algorithms, and user behaviour analytics. When suspicious activity is detected, automated workflows trigger alerts, isolate affected systems, and initiate forensic data collection.

Forensic investigation determines the cause, scope, and impact of a data breach. Israeli HMOs engage forensic specialists to analyse logs, examine compromised systems, and reconstruct event sequences. Root cause analysis identifies the vulnerabilities or policy failures that enabled the breach. Organisations categorise root causes into technical failures, process gaps, or human errors and implement corrective actions to prevent recurrence. Forensic reports document findings, root causes, and remediation steps.

Breach notification requires coordination between legal, compliance, communications, and technical teams. Israeli HMOs prepare notification templates in advance. Notifications to the Privacy Protection Authority include the nature of the breach, the categories and volume of data affected, the estimated number of individuals impacted, and the measures taken to mitigate harm. Notifications to affected individuals must be clear, accurate, and actionable. Organisations explain what data was compromised, what risks individuals face, and what steps they should take. Israeli HMOs maintain open lines of communication with the Privacy Protection Authority, providing timely updates as investigations progress.

Integrating Data Security Posture Management with Compliance Enforcement

DSPM platforms provide visibility into where biometric and genetic data resides, who has access, how it is classified, and whether security controls are enforced. Israeli HMOs deploy DSPM tools to discover sensitive data across on-premises and cloud environments, assess security configurations, and identify policy violations. DSPM platforms integrate with data classification engines that automatically label biometric and genetic data based on content inspection. Classification metadata drives access control policies, encryption enforcement, and audit logging.

DSPM tools generate risk scores for data assets based on factors such as sensitivity, access patterns, encryption status, and compliance posture. High-risk assets are flagged for immediate remediation, and organisations implement automated workflows to enforce security policies. DSPM platforms integrate with identity and access management systems, data loss prevention tools, and encryption solutions, enabling centralised policy enforcement across distributed environments.

Continuous monitoring ensures that biometric and genetic data remains protected as environments evolve. Israeli HMOs implement automated workflows that monitor data repositories, assess configuration changes, and enforce security policies in real time. When a policy violation is detected, automated workflows trigger alerts, revoke unauthorised access, and initiate remediation tasks. Continuous monitoring also supports compliance reporting. DSPM platforms generate dashboards that display compliance status, policy violations, and remediation progress, providing real-time visibility into Amendment 13 compliance posture.

Balancing Clinical Workflows with Regulatory and Security Requirements

Israeli HMOs must balance Amendment 13 compliance with the operational realities of healthcare delivery. Clinicians require rapid access to genetic data for diagnosis and treatment decisions. Researchers need access to biometric data for studies. Security controls that impede these workflows reduce efficiency and may compromise patient care.

Organisations design security architectures that enforce compliance without introducing unnecessary friction. This requires understanding clinical workflows, identifying points where sensitive data is accessed or transmitted, and implementing controls that are transparent to authorised users. Multi-factor authentication is enforced at login but not for every subsequent access. Encryption is applied automatically without requiring clinician intervention. Access controls are role-based, ensuring that clinicians see only the data relevant to their responsibilities.

Israeli HMOs engage clinicians, researchers, and administrative staff during security architecture design, gathering feedback and testing workflows before deployment. Organisations provide security awareness training on data privacy principles, consent management, and incident reporting, ensuring that staff are equipped to handle biometric and genetic data responsibly.

Content-aware controls inspect data in transit, classify it based on sensitivity, and enforce policies dynamically. Israeli HMOs implement content-aware proxies and data loss prevention tools that monitor email, file transfers, and application traffic for biometric and genetic data. When sensitive data is detected, content-aware controls enforce policies such as blocking transmission, requiring additional authentication, or encrypting data automatically. Policies are configured to balance security with operational needs.

Conclusion

Israeli HMOs demonstrate that organisations can meet Amendment 13 requirements whilst supporting clinical excellence and research innovation. Compliance requires layered technical controls, role-based access enforcement, AES-256 encryption at rest and in transit, and comprehensive audit trails. Organisations that succeed combine policy-driven governance with technical enforcement, ensuring that biometric and genetic data remains protected, traceable, and audit-ready.

Effective compliance depends on visibility into where sensitive data resides, who accesses it, and whether security controls are enforced. Data security posture management platforms provide this visibility and integrate with identity management systems, encryption solutions, and logging platforms. Continuous monitoring and automated policy enforcement ensure that security posture adapts to evolving threats and regulatory expectations. Audit trails are the foundation of regulatory defensibility. Immutable logging platforms capture every access event, providing tamper-evident evidence of compliance. Integration with SIEM, SOAR, and compliance reporting platforms enables organisations to detect anomalies, respond to incidents, and generate audit reports on demand. Israeli HMOs that implement these capabilities demonstrate accountability, reduce risk, and protect patient trust.

Looking ahead, the Privacy Protection Authority is intensifying its scrutiny of genetic data sharing with research institutions and cross-border transfers, moving beyond procedural review toward assessment of real-time technical controls. Regulators increasingly expect HMOs to demonstrate dynamic consent management and purpose-limitation enforcement through automated systems rather than static documentation. At the same time, the emergence of polygenic risk scoring and AI-driven genomic analysis as clinical and research tools is introducing new categories of processing activity that require explicit governance frameworks. Organisations that establish governance infrastructure for these capabilities now — before regulatory mandates crystallise — will be better positioned to demonstrate compliance as the enforcement landscape evolves.

How the Kiteworks Private Data Network Helps Israeli HMOs Secure Biometric and Genetic Data Under Amendment 13

The Private Data Network provides a unified platform for securing biometric and genetic data in motion. It enforces zero trust security and content-aware controls, ensuring that sensitive data is encrypted with AES-256, access is authenticated, and every interaction is logged. Kiteworks integrates with SIEM, SOAR, and ITSM platforms, enabling organisations to automate compliance workflows, detect policy violations, and respond to incidents rapidly. With compliance mappings for Amendment 13 and other regulatory frameworks, Kiteworks helps Israeli HMOs translate regulatory obligations into technical enforcement, reducing audit burden and ensuring defensibility.

Israeli HMOs face complex compliance obligations when securing biometric and genetic data under Amendment 13. Organisations must encrypt data at rest and in transit, enforce role-based and attribute-based access controls, maintain immutable audit trails, and manage third-party processors with rigorous oversight. These requirements extend across on-premises systems, cloud environments, and external data exchanges with laboratories, research institutions, and government agencies.

Kiteworks supports compliance with Amendment 13 by providing pre-built mappings to regulatory obligations, automating evidence collection, and generating audit reports on demand. Organisations can demonstrate to regulators that biometric and genetic data is protected throughout its lifecycle, that access controls are enforced consistently, and that every interaction is documented. Integration with SOAR and ITSM platforms enables automated incident response workflows, reducing mean time to detect and remediate incidents.

Israeli HMOs that deploy Kiteworks gain unified visibility into sensitive data exchanges, enforce content-aware policies without disrupting clinical workflows, and reduce the operational burden of compliance. The platform scales to support high-volume data transfers, integrates with existing security infrastructure, and provides the auditability and defensibility required for regulatory confidence.

Schedule a custom demo to see how Kiteworks enables your organisation to secure biometric and genetic data, operationalise Amendment 13 compliance, and protect patient trust.